Geovax Labs (GOVX) Stock
Early stage vaccine developer for infectious diseases. Here's the price, business snapshot, and what's worth knowing about Geovax Labs in October 2026.
Geovax Labs Inc (GOVX) is a clinical-stage biotechnology company developing vaccines using a Modified Vaccinia Ankara virus-like particle (MVA‑VLP) platform. The company has focused on infectious disease targets and aims to elicit robust immune responses through its platform. As a micro‑cap (market capitalisation around $17.2m), Geovax is a speculative, early‑stage investment: clinical data, regulatory decisions and financing events tend to be the primary value drivers. Investors should be aware of common biotech risks — trial setbacks, regulatory hurdles, limited revenues and potential dilution from capital raises — alongside the potential upside if clinical proof‑of‑concept is achieved. This summary is for general educational purposes only and not personalised investment advice. Suitability depends on an individual’s risk tolerance, time horizon and portfolio diversification. Past performance is not an indicator of future results; values can fall as well as rise and returns are not guaranteed.
Geovax Labs (GOVX) Stock Forecast
Analyst price target, next 12 months
$48.40
+23395.1% vs today's $0.21
Price range over the last 12 months
Close to its 12-month low
Analysts covering Geovax Labs have a consensus 12-month target of $48.40, above the current price of $0.21.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 17 Jun 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying GEOVAX Labs stock with a target price of $48.4, indicating strong growth potential.
Financial Health
GEOVAX LABS INC has a solid cash flow and book value per share, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Platform Potential
Geovax’s MVA‑VLP platform underpins its vaccine candidates and could offer differentiation if clinical proof emerges, though outcomes are uncertain and long timelines are common.
Clinical Milestones
Trial data and regulatory updates are primary catalysts that can move the stock sharply in either direction; investors should expect binary event risk.
Funding & Liquidity
With a market capitalisation near $17m, Geovax is a micro‑cap with limited liquidity and potential need for further financing, which can dilute existing holders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
